Sökning: onr:"swepub:oai:gup.ub.gu.se/282643" >
Using prognosis to ...
Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer
-
- Gnanapragasam, V. J. (författare)
- Univ Cambridge, Acad Urol Grp, Dept Surg, Box 279 S4,Cambridge Biomed Campus, Cambridge CB2 0QQ, England;Cambridge Univ Hosp NHS Trust, Dept Urol, Cambridge, England;Univ Cambridge, Cambridge Urol Translat Res & Clin Trials, Cambridge Biomed Campus, Cambridge, England
-
- Barrett, T. (författare)
- Univ Cambridge, Dept Radiol, Cambridge, England
-
- Thankapannair, V. (författare)
- Cambridge Univ Hosp NHS Trust, Dept Urol, Cambridge, England
-
visa fler...
-
- Thurtle, D. (författare)
- Univ Cambridge, Acad Urol Grp, Dept Surg, Box 279 S4,Cambridge Biomed Campus, Cambridge CB2 0QQ, England
-
- Rubio-Briones, J. (författare)
- Fdn Inst Valenciano Oncol, Valencia, Spain
-
- Domínguez-Escrig, J. (författare)
- Fdn Inst Valenciano Oncol, Valencia, Spain
-
- Bratt, Ola, 1963 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences,Gothenburg Univ, Sahlgrenska Acad, Gothenburg, Sweden
-
- Stattin, Pär (författare)
- Uppsala universitet,Urologkirurgi
-
- Muir, K. (författare)
- Univ Manchester, Dept Publ Hlth & Epidemiol, Manchester, Lancs, England
-
- Lophatananon, A. (författare)
- Univ Manchester, Dept Publ Hlth & Epidemiol, Manchester, Lancs, England
-
visa färre...
-
(creator_code:org_t)
- 2019-06-02
- 2019
- Engelska.
-
Ingår i: Bju International. - : Wiley. - 1464-4096 .- 1464-410X. ; 124:5, s. 758-767
- Relaterad länk:
-
https://www.reposito...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives: To test whether using disease prognosis can inform a rational approach to active surveillance (AS) for early prostate cancer. Patients and methods: We previously developed the Cambridge Prognostics Groups (CPG) classification, a five-tiered model that uses prostate-specific antigen (PSA), Grade Group and Stage to predict cancer survival outcomes. We applied the CPG model to a UK and a Swedish prostate cancer cohort to test differences in prostate cancer mortality (PCM) in men managed conservatively or by upfront treatment in CPG2 and 3 (which subdivides the intermediate-risk classification) vs CPG1 (low-risk). We then applied the CPG model to a contemporary UK AS cohort, which was optimally characterised at baseline for disease burden, to identify predictors of true prognostic progression. Results were re-tested in an external AS cohort from Spain. Results: In a UK cohort (n=3659) the 10-year PCM was 2.3% in CPG1, 1.5%/3.5% in treated/untreated CPG2, and 1.9%/8.6% in treated/untreated CPG3. In the Swedish cohort (n=27942) the10-year PCM was 1.0% in CPG1, 2.2%/2.7% in treated/untreated CPG2, and 6.1%/12.5% in treated/untreated CPG3. We then tested using progression to CPG3 as a hard endpoint in a modern AS cohort (n=133). During follow-up (median 3.5years) only 6% (eight of 133) progressed to CPG3. Predictors of progression were a PSA density ≥0.15ng/mL/mL and CPG2 at diagnosis. Progression occurred in 1%, 8% and 21% of men with neither factor, only one, or both, respectively. In an independent Spanish AS cohort (n=143) the corresponding rates were 3%, 10% and 14%, respectively. Conclusion: Using disease prognosis allows a rational approach to inclusion criteria, discontinuation triggers and risk-stratified management in AS. © 2019 The Authors. BJU International © 2019 BJU International Published by John Wiley & Sons Ltd
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- #PCSM
- #ProstateCancer
- Active surveillance
- Cambridge Prognostic Groups
- Intermediate-risk
- Localised prostate cancer
- Low-risk
- Stratified follow-up
- Localised prostate cancer
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Gnanapragasam, V ...
-
Barrett, T.
-
Thankapannair, V ...
-
Thurtle, D.
-
Rubio-Briones, J ...
-
Domínguez-Escrig ...
-
visa fler...
-
Bratt, Ola, 1963
-
Stattin, Pär
-
Muir, K.
-
Lophatananon, A.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Bju Internationa ...
- Av lärosätet
-
Göteborgs universitet
-
Uppsala universitet